NiQuitin CQ reclassification
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline seeks to change status of its 4 mg nicotine replacement therapy lozenges from Pharmacy to General Sale List in the UK, according to Feb. 10 filing with the Medicines Control Agency. GSK states NRT should be as "freely available" as nicotine, points out most NRT products already have GSL status. "Wider availability of NiQuitin CQ...is likely to lead to increased numbers of smokers stopping," petition says. Comments are due March 24...